Skip to main content

Table 2 KRAS and BRAF mutational status with outcomes

From: Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy

 

KRAS (n = 67)

BRAF (n = 64)

Wild-type (WT)

43 (64%)

61 (95%)

Mutant

24 (36%)

3 (5%)

Median OS WT

4.1 years

4.1 years

Median OS mutant

4.9 years p = 0.6

Not reached p = 0.1

WT vs. mutant

  

   Limited response

67% vs. 67%

69% vs. 33% (1 of 3)

   Major response

14% vs. 21%

16% vs. 0%

   Complete response

19% vs. 13% p = 0.7

15% vs. 66% (2 of 3)

WT vs. mutant

  

   Downstaged

42% vs. 38%

36% vs. 66% (2 of 3)

   No change or upstaged

58% vs. 63% p = 0.8

64% vs. 33% (1 of 3)

Recurrence

  

   None

67% vs. 54%

62% vs. 100% (3 of 3)

   Local recurrence

12% vs. 8%

10%

   Distant recurrence

14% vs. 29%

20%

   Both local and distant

7% vs. 8% p = 0.5

8%

  1. WT: Wildtype; OS: Overall Survival